Blog Archives

Scientific event on B-cell lymphomas

4/28/2016

Title: “Tradition and innovation in the treatment of low-grade B-cell lymphomas: where to from now?”

This was an interesting scientific event, organised in Athens (Hotel Divani Caravel), Greece on
Saturday, April 23, 2016.
The scientific program included three main sessions:
a) Follicular lymphoma: biological revelations and therapeutic advances.
b) CLL: understanding the biology for improving outcomes.
c) Making strides against CLL: harnessing biological knowledge for treating the disease.

Overall, this was a high-level educational experience, in particular regarding chronic lymphocytic leukemia (CLL), with an interesting opportunity for the audience to interact with the speakers via a question & answer tool.

0 Comments

CLLassify: The beginning...

4/1/2016

0 Comments

CLLassify is a highly innovative project that aspires to face the high-challenging and timely problems related to chronic lymphocytic leukemia (CLL), and in particular the classification and efficient prognosis of patients at the time of diagnosis and the attempt to personalize the treatment. CLLassify addresses these issues in a pioneering fashion within a multidisciplinary collaboration, proposing an improved classification of the patients, based on innovative statistical techniques as well as the novel aspect of personalized prediction of the need for treatment at a specific time point for the individual patient.
The specific research Objectives of CLLassify are to:
O1: Provide a new refined classification for early stage CLL patients, based on established and emerging prognostic factors and evaluate classification based on time dependent characteristics.
O2: Apply for the first time in CLL a novel class of statistical predictive models and, within the O1 groups, predict at a specific time point, the future need for treatment of an individual patient.
O3: Develop a package in the statistical programming language ‘R’, supported by a user’s manual.
Τhe scientific proposal CLLassify was successfully evaluated after a very competitive evaluation process with a total score of 97% (Excellence: 4.8/5, Impact: 4.9/5, Implementation: 4.9/5), within the framework of the European Actions Marie Skłodowska-Curie Individual Fellowships IF-EF (MSCA-IF-2015-EF). The proposal with full name “Innovative risk assessment for individualizing treatment in chronic lymphocytic leukemia” was submitted by the Postdoctoral Researcher, Dr. Theodoros Moysiadis (fellow), under the supervision of Dr. Kostas Stamatopoulos (Coordinator). Dr. Stamatopoulos is the Director of the Institute of Applied Biosciences (INAB), which is the Host Institute of CLLassify, situated within the Centre for Research and Technology Hellas, Greece. CLLassify started at April, 1, 2016 and will be completed at March, 31, 2018.

0 Comments

Scientific event on B-cell lymphomas

CLLassify: The beginning...

Author

Archives

Categories